Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 13,200 shares, a growth of 26.9% from the September 15th total of 10,400 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 13,400 shares, the short-interest ratio is presently 1.0 days.

Aprea Therapeutics Trading Down 0.8 %

NASDAQ APRE traded down $0.02 on Monday, reaching $2.58. The stock had a trading volume of 7,103 shares, compared to its average volume of 19,053. The company has a market capitalization of $14.01 million, a price-to-earnings ratio of -0.78 and a beta of 1.03. The business has a 50 day moving average price of $3.18 and a 200 day moving average price of $4.25. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts anticipate that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on APRE shares. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, August 12th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.